Busey Bank Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Busey Bank increased its stake in Novo Nordisk A/S (NYSE:NVO) by 108.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 106,434 shares of the company’s stock after buying an additional 55,380 shares during the period. Busey Bank’s holdings in Novo Nordisk A/S were worth $9,155,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the third quarter worth $42,000. Albion Financial Group UT raised its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the period. Finally, Sound Income Strategies LLC lifted its position in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.3 %

Shares of NVO stock opened at $84.05 on Thursday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The business’s fifty day moving average is $94.75 and its 200 day moving average is $114.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $377.17 billion, a PE ratio of 27.20, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.